Adial Pharmaceuticals Expands Patent For Genetic-Based Treatment For Addiction

Adial Pharmaceuticals, a biopharma company, announced that the United States Patent and Trademark Office (USPTO) issued patent number 12,226,401 on February 18, 2025, expanding its intellectual property for its genetic-based approach to treating alcohol use disorder and drug dependencies. The patent covers a method for identifying genetic markers linked to alcohol and opioid-related disorders. 

Cary Claiborne, CEO of Adial Pharmaceuticals, said in a statement, “This patent demonstrates our continued dedication to advancing science-driven solutions for diagnosing and treating addiction. Our patented approach, which uses genetic information to guide treatment, has the potential to transform how alcohol and opioid dependence are treated. We believe this personalised method not only enhances effectiveness but also provides new options to millions suffering from addiction by addressing the root causes on a molecular level.”

The analysis of the HTR3B gene's AC genotype and the HTR3A gene's AG genotype enables the creation of customised AD04 treatments from Adial Pharmaceuticals. The innovative approach allows healthcare providers to create patient-specific treatment methods that match each patient's genetic information. The company enhances drug protection to fulfil its mission of building better treatment results through safer addiction therapy alternatives than generalised techniques.